UBS O'Connor’s Ventyx Biosciences VTYX Stock Holding History

UBS O'Connor’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,000	Closed	-$116K	–	611
2023 Q3	$116K	Buy	+35,000	New	+$1.21M	﹤0.01%	461

Other funds holding VTYX

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS O'Connor's VTYX Position: Q3 2025 in Review

UBS O'Connor sold out of Ventyx Biosciences (VTYX) in Q3 2025, closing a stake of 79,000 shares — an estimated $169K sold.

UBS O'Connor first reported a position in VTYX in Q3 2022 and held it in 9 quarters. The position peaked at $1.92M in Q2 2023. 110 funds tracked by Wall St. Rank hold VTYX as of Q3 2025.

UBS O'Connor reported no remaining Ventyx Biosciences position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 79,000 Ventyx Biosciences shares in Q3 2025, an estimated $169K.
UBS O'Connor first reported a position in Ventyx Biosciences in Q3 2022 and held it in 9 quarters.
UBS O'Connor's Ventyx Biosciences position peaked at $1.92M in Q2 2023.
110 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.